Abstract
Background and Objectives Testing strategies for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in school settings are needed to assess the efficacy of infection mitigation strategies and inform school reopening policies. We hypothesized that supervised serial self-collected non-nasopharyngeal testing in summer camp settings would be acceptable and feasible.
Methods We performed a cohort study at two urban day camps for kindergarten-8th graders in June and July 2020. Eligible participants were campers, up to two adult household contacts, and camp staff. We assessed participation rates for providing, at two time points, supervised, self-collected anterior nares samples for reverse transcription polymerase chain reaction (RT-PCR) and saliva samples for antibody testing. We qualitatively assessed testing feasibility and adherence to stated camp infection mitigation strategies.
Results 76% (186/246) of eligible participants consented. The cohort completing both rounds of testing (n=163) comprised 67 campers, 76 household contacts, and 20 staff. Among those present, 100% of campers and staff completed test collection at both time points. Testing was feasible to implement, including staff participation supervising camper test collection. No virus was detected by RT-PCR; seven participants had antibodies. Observed adherence to stated camp mitigation policies for masking, physical distancing, and stable cohorting was generally high.
Conclusions Supervised, self-collected serial anterior nasal and saliva-based SARS-CoV-2 testing was acceptable, with successful repeated participation by children ages 5-14. This strategy for testing and the observed infection mitigation practices comprise potential core components for safe school reopening.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by funding from the UCSF Chancellor's Fund. The Chan Zuckerberg Biohub donated proteins used in the antibody assay. Author Bryan Greenhouse is a Chan Zuckerberg Biohub investigator.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at UCSF approved this study as public health surveillance
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Disclosure: The authors have no conflicts of interest relevant to this article to disclose.
Funding/Support: This project is supported by funding from the UCSF Chancellor’s Fund. The Chan Zuckerberg Biohub donated proteins used in the antibody assay. BG is a Chan Zuckerberg Biohub investigator.
Data Availability
Data not currently posted for public viewing
Abbreviations
- CDC
- Centers for Disease Control and Prevention;
- COVID-19
- coronavirus disease 2019;
- NP
- nasopharyngeal;
- PPE
- personal protective equipment;
- RT-PCR
- reverse transcription polymerase chain reaction;
- SARS CoV-2
- severe acute respiratory syndrome coronavirus 2;
- UCSF
- University of California, San Francisco.